Harrow closes TYRVAYA nasal spray acquisition from Viatris for USD 30 million upfront
Bitget2026/10/05 11:06Harrow closed its acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris, gaining worldwide rights except Japan. Viatris retained Japan commercialization rights, agreeing to pay Harrow royalties on any future net sales there. Deal terms include USD 30 million cash paid at closing, with up to USD 70 million tied to net-sales milestones. Harrow expects TYRVAYA revenue to exceed USD 30 million in 2027 as it integrates the brand into its ocular surface franchise. Roughly 40 Viatris personnel are expected to join in Q4 2026 to expand Harrow’s dry-eye commercial team. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9839258) on October 05, 2026, and is solely responsible for the information contained therein.
- Harrow closed its acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris, gaining worldwide rights except Japan.
- Viatris retained Japan commercialization rights, agreeing to pay Harrow royalties on any future net sales there.
- Deal terms include USD 30 million cash paid at closing, with up to USD 70 million tied to net-sales milestones.
- Harrow expects TYRVAYA revenue to exceed USD 30 million in 2027 as it integrates the brand into its ocular surface franchise.
- Roughly 40 Viatris personnel are expected to join in Q4 2026 to expand Harrow’s dry-eye commercial team.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
